Bms-986158, A Potent Bet Inhibitor, As Monotherapy And In Combination With Ruxolitinib Or Fedratinib In Intermediate- Or High-Risk Myelofibrosis (Mf): Results From A Phase 1/2 Study
BMS-986158;Fedratinib;Ruxolitinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Bms-986158, A Potent Bet Inhibitor, As Monotherapy And In Combination With Ruxolitinib Or Fedratinib In Intermediate- Or High-Risk Myelofibrosis (Mf): Results From A Phase 1/2 Study ### Output: BMS-986158;Fedratinib;Ruxolitinib